3-Methyl-3-[3-methyl-3-(methylamino)butoxy]butan-1-ol

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-Methyl-3-[3-methyl-3-(methylamino)butoxy]butan-1-ol
• 英文别名: 3-methyl-3-[3-methyl-3-(methylamino)butoxy]butan-1-ol
• 化学式: C₁₁H₂₅NO₂
• 分子量: 203.32
• InChiKey: ZMFPJIGCCSKQTL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  41.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Tetracyclic anthraquinone derivatives
  申请人：TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD.

  公开号：US10294260B2

  公开（公告）日：2019-05-21

  Disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, W, n are defined as in the present application. Also disclosed is a method for treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound and a salt thereof according to the present application possess good anticancer and/or antitumor activity, and good water solubility and stability, as well as good tolerance in animal bodies. Also disclosed is a process for preparing a compound represented by formula (I) of the present application.

  公开了一种由式 (I) 代表的化合物及其药学上可接受的盐、 其中 R1、R2、R3、R4、R5、W、n 的定义与本申请相同。还公开了一种治疗癌症的方法，包括向有需要的受试者施用治疗有效量的式 (I) 所代表的化合物或其药学上可接受的盐。根据本申请的化合物及其盐具有良好的抗癌和/或抗肿瘤活性、良好的水溶性和稳定性，以及在动物体内良好的耐受性。本申请还公开了一种制备式（I）所代表的化合物的工艺。
• [EN] TETRACYCLIC ANTHRAQUINONE DERIVATIVES<br/>[FR] DÉRIVÉS D'ANTHRAQUINONE TÉTRACYCLIQUE
  申请人：TIANJIN HEMAY BIO TECH CO LTD

  公开号：WO2014059740A1

  公开（公告）日：2014-04-24

  公开了式(I)所示的化合物及其药物可接受的盐，其中，R1、R2、R3、R4、R5、W、n如本申请中所定义。
• TETRACYCLIC ANTHRAQUINONE DERIVATIVES
  申请人：Tianjin Hemay Bio-Tech Co., Ltd.

  公开号：EP2824108B1

  公开（公告）日：2017-04-19
• Colloid Bonded Medicinal Compounds
  申请人：B. Braun Melsungen AG

  公开号：US20150202307A1

  公开（公告）日：2015-07-23

  The invention relates to colloids bound medicinal compounds or fluorescent markers, to a process for the preparation thereof, and to a pharmaceutical formulation containing such compounds.
• US9737613B2
  申请人：——

  公开号：US9737613B2

  公开（公告）日：2017-08-22